

**MTN 011 - A Phase 1 Impact of Coitus on Pharmacokinetics Pharmacodynamics of Tenofovir 1% Gel Following Pericoital or Daily Gel Dosing
Data as of July 30, 2015**

Visit Adherence: Completion of Procedures by Site

	Cleveland, OH	Pittsburgh, PA	All Sites
Participants Enrolled	26	36	62
Pelvic Exams Required and Expected	83	107	190
Completed	81 (97.6%)	107 (100.0%)	188 (98.9%)
Not Completed	2 (2.4%)	0 (0.0%)	2 (1.1%)
Pregnancy Tests Required and Expected	60	82	142
Completed	60 (100.0%)	80 (97.6%)	140 (98.6%)
Not Completed	0 (0.0%)	2 (2.4%)	2 (1.4%)
HIV-1 Test Required and Expected	24	33	57
Completed	24 (100.0%)	33 (100.0%)	57 (100.0%)
Pre-coital pH Required and Expected	85	115	200
Completed	84 (98.8%)	113 (98.3%)	197 (98.5%)
Not Completed	1 (1.2%)	2 (1.7%)	3 (1.5%)
Post-coital pH Required and Expected	58	71	129
Completed	57 (98.3%)	70 (98.6%)	127 (98.4%)
Not Completed	1 (1.7%)	1 (1.4%)	2 (1.6%)
Height measured during PK Required and Expected	12	17	29
Completed	12 (100.0%)	17 (100.0%)	29 (100.0%)
Weight measured during PK Required and Expected	82	104	186
Completed	80 (97.6%)	103 (99.0%)	183 (98.4%)
Not Completed	2 (2.4%)	1 (1.0%)	3 (1.6%)
CVL collection Required and Expected	82	104	186
Completed	81 (98.8%)	103 (99.0%)	184 (98.9%)
Not Completed	1 (1.2%)	1 (1.0%)	2 (1.1%)
CVL - Supernatant Required and Expected	82	104	186
Completed	81 (98.8%)	103 (99.0%)	184 (98.9%)
Not Completed	1 (1.2%)	1 (1.0%)	2 (1.1%)

**MTN 011 - A Phase 1 Impact of Coitus on Pharmacokinetics Pharmacodynamics of Tenofovir 1% Gel Following Pericoital or Daily Gel Dosing
Data as of July 30, 2015**

Visit Adherence: Completion of Procedures by Site

	Cleveland, OH	Pittsburgh, PA	All Sites
CVL - Cell Pellet Required and Expected	82	104	186
Completed	81 (98.8%)	103 (99.0%)	184 (98.9%)
Not Completed	1 (1.2%)	1 (1.0%)	2 (1.1%)
Vaginal Tissue Biopsy Required and Expected	58	73	131
Completed	57 (98.3%)	72 (98.6%)	129 (98.5%)
Not Completed	1 (1.7%)	1 (1.4%)	2 (1.5%)
Cervical Tissue Biopsy Required and Expected	58	73	131
Completed	57 (98.3%)	72 (98.6%)	129 (98.5%)
Not Completed	1 (1.7%)	1 (1.4%)	2 (1.5%)
Cervical Cytobrush Required and Expected	58	73	131
Completed	57 (98.3%)	72 (98.6%)	129 (98.5%)
Not Completed	1 (1.7%)	1 (1.4%)	2 (1.5%)
Blood Draw Required and Expected	58	73	131
Completed	57 (98.3%)	72 (98.6%)	129 (98.5%)
Not Completed	1 (1.7%)	1 (1.4%)	2 (1.5%)
Rectal Sponge Required and Expected	58	73	131
Completed	57 (98.3%)	72 (98.6%)	129 (98.5%)
Not Completed	1 (1.7%)	1 (1.4%)	2 (1.5%)
CASI Baseline Questionnaire (BAQ) Required and Expected	26	36	62
Completed	24 (92.3%)	34 (94.4%)	58 (93.5%)
Not Completed	2 (7.7%)	2 (5.6%)	4 (6.5%)
Female CASI Baseline Behavioral Questionnaire Required and Expected	13	18	31
Completed	12 (92.3%)	18 (100.0%)	30 (96.8%)
Not Completed	1 (7.7%)	0 (0.0%)	1 (3.2%)
Female CASI Follow up Behavioral Questionnaire Required and Expected	58	76	134
Completed	57 (98.3%)	73 (96.1%)	130 (97.0%)
Not Completed	1 (1.7%)	3 (3.9%)	4 (3.0%)

**MTN 011 - A Phase 1 Impact of Coitus on Pharmacokinetics Pharmacodynamics of Tenofovir 1% Gel Following Pericoital or Daily Gel Dosing
Data as of July 30, 2015**

Visit Adherence: Completion of Procedures by Site

	Cleveland, OH	Pittsburgh, PA	All Sites
Female CASI Exit Acceptability Questionnaire Required and Expected	12	16	28
Completed	12 (100.0%)	16 (100.0%)	28 (100.0%)
Male CASI Exit Acceptability Questionnaire Required and Expected	12	16	28
Completed	12 (100.0%)	16 (100.0%)	28 (100.0%)
Male Practices Questionnaire Required and Expected	48	56	104
Completed	48 (100.0%)	56 (100.0%)	104 (100.0%)